Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	NST-628
Synonyms
Therapy Description	NST-628 stabilizes the RAF-MEK complex, which inhibits MEK/ERK/RSK phosphorylation and reactivation of the pathway, potentially leading to tumor growth inhibition (PMID: 38588399).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
NST-628		NST628\|NST 628	MEK inhibitor (Pan) 27 RAF Inhibitor (Pan) 29	NST-628 stabilizes the RAF-MEK complex, which inhibits MEK/ERK/RSK phosphorylation and reactivation of the pathway, potentially leading to tumor growth inhibition (PMID: 38588399).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 6 of 6 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
BRAF D594E HRAS Q61L	melanoma	sensitive	NST-628	Preclinical - Pdx	Actionable	In a preclinical study, NST-628 treatment resulted in an overall response rate of 69.5% in a panel of patient-derived xenograft (PDX) models of solid tumors harboring RAS-MAPK pathway alterations, including a response in a melanoma patient-derived xenograft (PDX) model harboring BRAF D594E and HRAS Q61L (PMID: 38588399).	38588399
BRAF D594N	lung adenocarcinoma	predicted - sensitive	NST-628	Preclinical - Pdx	Actionable	In a preclinical study, NST-628 treatment resulted in an overall response rate of 69.5% in a panel of patient-derived xenograft (PDX) models of solid tumors harboring RAS-MAPK pathway alterations, including 1 response out of 2 lung adenocarcinoma patient-derived xenograft (PDX) models harboring BRAF D594N (PMID: 38588399).	38588399
BRAF G469A	lung sarcomatoid carcinoma	sensitive	NST-628	Preclinical - Pdx	Actionable	In a preclinical study, NST-628 treatment resulted in an overall response rate of 69.5% in a panel of patient-derived xenograft (PDX) models of solid tumors harboring RAS-MAPK pathway alterations, including a response in a lung sarcomatoid carcinoma patient-derived xenograft (PDX) model harboring BRAF G469A (PMID: 38588399).	38588399
BRAF G469E NRAS G13V	melanoma	sensitive	NST-628	Preclinical - Pdx	Actionable	In a preclinical study, NST-628 treatment resulted in an overall response rate of 69.5% in a panel of patient-derived xenograft (PDX) models of solid tumors harboring RAS-MAPK pathway alterations, including a response in a melanoma patient-derived xenograft (PDX) model harboring BRAF G469E and NRAS G13V (PMID: 38588399).	38588399
NRAS Q61L	melanoma	sensitive	NST-628	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NST-628 inhibited viability of a melanoma cancer cell line harboring NRAS Q61L in culture and inhibited tumor growth and induced tumor regression in a cell line xenograft model (PMID: 38588399).	38588399
NRAS Q61R	melanoma	sensitive	NST-628	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NST-628 inhibited viability of a melanoma cancer cell line harboring NRAS Q61R in culture and induced tumor regression in an intracranial cell line xenograft model (PMID: 38588399).	38588399

Showing 1 to 6 of 6 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT06326411	Phase I	NST-628	A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)	Recruiting	USA \| AUS	0

Showing 1 to 1 of 1 entries

Filter rows:

Additional content available in CKB BOOST